Previous 10 | Next 10 |
10x Genomics (NASDAQ: TXG) has come a long way since opening its doors in 2012. The genomics company now has a market cap of close to $20 billion. In this video recorded on March 11, 2021 , Motley Fool contributor Keith Speights talks with 10x Genomics CEO and co-founder Se...
Gene editing technology holds the potential to transform how many diseases are treated. It could even offer the promise of curing some genetic diseases. However, as is the case with many types of technology, there are also some significant risks. In this video recorded on March 11, 2021 ...
What does the future of healthcare hold? Look for incredible advances. In this video recorded on March 11, 2021 , Motley Fool CEO and co-founder Tom Gardner talks with 10x Genomics (NASDAQ: TXG) CEO and co-founder Serge Saxonov about what he thinks healthcare will look like...
PLEASANTON, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today announced the launch of its Chromium Single Cell Gene Expression Low Throughput (LT) Kit, a new offering designed to put the power of single cell analysis within the reach of more scientis...
Gainers: [[GTAT]] +49%. [[PFIN]] +13.6%. [[RYTM]] +5.6%. [[WING]] +3.8%. [[CLNE]] +3.1%.Losers: [[DISCB]] -10.9%. [[WMG]] -8.9%. [[TLS]] -7.7%. [[TXG]] -7.1%. [[BCEL]] -6.9%. For further details see: GTAT, PFIN, DISCB and BCEL among after-hours movers
Biotech company 10x Genomics (NASDAQ: TXG) manufactures equipment that helps researchers better analyze how a single cell functions and interacts with another single cell. Think of the company's technology like gracefully peeling back the layers of an onion, one layer at a time -- a...
TXG is a life sciences company trading at 58x P/S and 23x P/B, with a history of negative earnings. The current market price is implying that the company already has 25% of the life sciences research tools market; in reality, it only has 0.5%. Insiders have been consistently selli...
Dan Loeb's 13F portfolio value increased from ~$10B to ~$13B this quarter. The number of positions increased from 47 to 73. Third Point added Alphabet and increased Avantor and Planet Fitness while reducing Amazon.com and Alibaba Group Holdings. The top three positions are at ~20%...
City to Change Street Name to ‘Genomics Place’ PLEASANTON, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today announced expansion plans to support the company’s continued growth in Pleasanton across two properties. Along w...
The growing market of gene therapies enhances Illumina's growth prospects. Illumina has a strong balance sheet opening an opportunity to gain exposure to the rising market of personalized medicine without the risk of investing in biotech. The acquisition of Grail capitalizes on th...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...